SG Americas Securities LLC lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 54.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,140 shares of the company's stock after purchasing an additional 6,373 shares during the period. SG Americas Securities LLC's holdings in Recursion Pharmaceuticals were worth $193,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Strs Ohio grew its stake in shares of Recursion Pharmaceuticals by 41.8% in the 2nd quarter. Strs Ohio now owns 20,700 shares of the company's stock worth $168,000 after purchasing an additional 6,100 shares during the last quarter. CWM LLC grew its stake in shares of Recursion Pharmaceuticals by 99.3% in the 3rd quarter. CWM LLC now owns 8,990 shares of the company's stock worth $96,000 after purchasing an additional 4,480 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $442,000. Centaurus Financial Inc. acquired a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $82,000. Finally, US Bancorp DE acquired a new position in shares of Recursion Pharmaceuticals in the second quarter worth about $132,000. Institutional investors and hedge funds own 63.62% of the company's stock.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $9.37 on Friday. The stock has a market cap of $1.78 billion, a P/E ratio of -6.51 and a beta of -0.32. The firm has a 50 day simple moving average of $8.36 and a 200 day simple moving average of $9.77. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18.

Wall Street Analyst Weigh In

Several brokerages have commented on RXRX. SVB Leerink decreased their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Monday, January 23rd. The Goldman Sachs Group raised their target price on shares of Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Wednesday, November 9th.

Insider Buying and Selling

In related news, COO Tina Marriott Larson sold 16,000 shares of the firm's stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $10.96, for a total transaction of $175,360.00. Following the completion of the sale, the chief operating officer now directly owns 203,654 shares in the company, valued at $2,232,047.84. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott Larson sold 16,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, November 17th. The shares were sold at an average price of $10.96, for a total value of $175,360.00. Following the completion of the sale, the chief operating officer now directly owns 203,654 shares in the company, valued at $2,232,047.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Shafique Virani sold 10,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $12.31, for a total transaction of $123,100.00. Following the completion of the sale, the insider now owns 83,160 shares of the company's stock, valued at $1,023,699.60. The disclosure for this sale can be found here. Over the last three months, insiders purchased 322,253 shares of company stock worth $2,427,260 and sold 179,905 shares worth $1,642,155. 22.25% of the stock is currently owned by corporate insiders.

Recursion Pharmaceuticals Company Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Recommended Stories

• Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
• Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
• Mullen Automotive Stock Gains Momentum On Positive News
• Harley-Davidson Inc. Stock, Is It Time To Buy?
• The Bottom Is In For Meta Platforms, Volatility Is Not Over
• Analyzing Alaska Air's Recent Earnings

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.